BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
TXNM Energy, Inc. (NYSE – TXNM)
Under the terms of the agreement, TXNM Energy will be acquired by Blackstone Infrastructure for $61.25 per share in cash, reflecting a total enterprise value of $11.5 billion. The investigation concerns whether the TXNM Energy Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/txnm-energy-inc-nyse-txnm/.
Inozyme Pharma, Inc. (Nasdaq – INZY)
Under the terms of the Merger Agreement, Inozyme Pharma will be acquired by BioMarin Pharmaceutical Inc. (“BioMarin”) (Nasdaq – BMRN) for $4.00 per Inozyme Pharma share in an all-cash transaction for a total consideration of approximately $270 million. The investigation concerns whether the Inozyme Pharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/inozyme-pharma-inc-nasdaq-inzy/.
Servotronics, Inc. (NYSE American – SVT)
Under the terms of the agreement, Servotronics will be acquired by TransDigm for $38.50 per share in cash, in a transaction valued at approximately $110 million. The investigation concerns whether the Servotronics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/servotronics-inc-nyse-american-svt/.
Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
Under the terms of the Merger Agreement, Protagenic Therapeutics will be acquired by Phytanix Bio Inc. (“Phytanix”) Ownership of the combined company will be approximately 35% for Protagenic Therapeutics stockholders and approximately 65% for Phytanix stockholders. The investigation concerns whether the Protagenic Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/protagenic-therapeutics-inc-nasdaq-ptix/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow